Figure 8

Comparison of Plaque Reduction neutralization to pseudovirus neutralization or ELISA binding. Panel (A): Comparison of 50% plaque reduction neutralization titres (PRNT) using LASV lineage II (0043/LV/14) versus PRNT using LASV lineage IV (Josiah) at Biosafety level-4. Panel (B): Comparison of 50% reciprocal neutralization titres using LASV pseudoviruses (pv) expressing the glycoprotein complex (GPC) of LASV lineage II versus LASVpv expressing GPC of LASV lineage IV (Josiah). Panel (C): Comparison of PRNT reciprocal titres using LASV lineage II to LASV pseudoviruses expressing LASV lineage II GPC reciprocal neutralization titres. Panel (D): Comparison of PRNT reciprocal titres using LASV lineage IV to LASV pseudoviruses expressing LASV lineage IV GPC reciprocal neutralization titres. Panel (E): Comparison of PRNT reciprocal titres using LASV lineage II to 50% reciprocal binding titres to prefusion glycoprotein (Pf-GP) of LASV lineage II. Panel (F): Comparison of PRNT reciprocal titres using LASV lineage IV to 50% reciprocal binding titres to Pf-GP of LASV lineage IV. Panel (G): Comparison of LASV pseudoviruses expressing lineage II GPC reciprocal titres to 50% reciprocal binding titres to Pf-GP of LASV lineage II. Panel (H): Comparison of LASV pseudoviruses expressing lineage IV GPC reciprocal titres to 50% reciprocal binding titres to Pf-GP of LASV lineage IV. Data was analyzed using Microsoft Excel (version 16.39, Microsoft, Redmond, WA) and JMP software (version 13.0.0, SAS Institute, Inc., Cary, NC). The figure was compiled using Adobe Illustrator (version 15.1.0, San Jose, CA). Note that multiple samples had the same 50% reciprocal titres producing overlapping data points.